Lv6
2070 积分 2022-07-05 加入
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
1小时前
待确认
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1小时前
待确认
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
2小时前
待确认
Pembrolizumab for Early Triple-Negative Breast Cancer
2小时前
待确认
Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study
2小时前
待确认
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
15小时前
待确认
Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases
1天前
待确认
EGFR activation limits the response of liver cancer to lenvatinib
4天前
已完结
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
4天前
已完结
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
7天前
已完结
皖公网安备34019202002308
